Arterra Bioscience S.p.A.

Equities

ABS

IT0005386369

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 16:44:59 17/05/2024 BST			5-day change	1st Jan Change
1.98 ^EUR	+0.51%		+0.51%	+19.28%

05-08	Mib bearish; focus on quarterlies	AN
05-07	Mib still in the green; Campari drags bullishness	AN

Arterra Bioscience increases turnover by 26 percent in first quarter

May 06, 2024 at 10:50 am

(Alliance News) - Arterra Bioscience Spa on Monday reported that in the first quarter of the year it increased sales by 26 percent to EUR1.1 million from EUR862,870 as of March 31, 2023.

Maria Gabriella Colucci, Co-Founder, President and CEO of Arterra Bioscience, commented, "This increase confirms the sales trend highlighted in the press release issued following the approval of the financial statements for the year ended December 31, 2023."

"In fact, in the previous fiscal year, while showing a contraction in sales, there was a clear recovery in the last months of 2023; a recovery that continues in these early months of 2024 and allows us to be confident about achieving the 2024 targets."

Arterra Bioscience trades in the green by 3.2 percent at EUR1.96 per share.

By Claudia Cavaliere, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Go to the original article.
Legal disclaimer

Latest news about Arterra Bioscience S.p.A.

Mib bearish; focus on quarterlies	05-08	AN
Mib still in the green; Campari drags bullishness	05-07	AN
Indices in green; Iren hurt after Ad shutdown	05-07	AN
Stock markets up; results push UniCredit and Simone	05-07	AN
Mib in green; UniCredit and MPS boost profit	05-07	AN
Mib caresses 34,000; Amplifon bullish	05-06	AN
Arterra Bioscience increases turnover by 26 percent in first quarter	05-06	AN
ITALY GROWTH WINNERS & LOSERS: Askoll EVA rallying; Alfonsino trailing.	04-24	AN
Arterra Bioscience with profit down; board confirms dividend	04-02	AN
Futures down; China sets growth at 5 percent	03-05	AN
Mib slightly down; still strength on Saipem	03-04	AN
Mib opens higher, still good for banks	02-23	AN
Arterra, decree consessione agevolzioni bando Rome Technopole	02-15	AN
Arterra Bioscience closes 2023 with declining revenues	02-13	AN
Banks weigh on Mib in the red	02-13	AN
Futures down slightly; wait for U.S. CPI	02-13	AN
Mib bullish dragged by Saipem and Cucinelli	02-12	AN
Mib bullish; profit taking on MPS	02-08	AN
Arterra Bioscience closes nine months with revenues up	11-07	AN
Arterra Bioscience S.p.A.'s Equity Buyback announced on May 13, 2022, has expired.	27/10/23	CI
Arterra Bioscience buys back own shares for approximately EUR30,000	27/10/23	AN
Arterra Bioscience has purchased more than 11,200 of its own ordinary shares	20/10/23	AN
Arterra Bioscience has purchased more than 26,000 of its own ordinary shares	13/10/23	AN
Arterra Bioscience buys back own shares for more than EUR30,000	06/10/23	AN
Arterra Bioscience reduces profit in half-year; production value down	28/09/23	AN

Chart Arterra Bioscience S.p.A.

Duration

Period

More charts

Company Profile

Arterra Bioscience SpA is an Italy-based biotechnology company. It focuses on research and development of ingredients and natural solutions. By exploiting the potentialities of living organisms such as bacteria, yeasts, plants and animal cells, the Company develops products and processes that serve as enabling technologies and that find horizontal application in various industrial sectors, such as cosmetics, agriculture and nutraceutics. The Companyâs main activities and applications include development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds and the production of high-tech raw materials with application in different industrial fields. The Company collaborates with private companies, universities and research institutes all over the world.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARTERRA BIOSCIENCE S.P.A.	+19.28%	14.33M
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-6.26%	11.42B

Other Biotechnology & Medical Research